Analyzing Sobi's Remarkable Q4 and Full Year 2025 Growth
S Swedish Orphan Biovitrum AB (publ) announced an impressive report, showcasing their solid performance for the fourth quarter and the full year of 2025, establishing a foundation for sustainable growth.
Fourth Quarter Highlights
In the fourth quarter of 2025, Sobi reported total revenue reaching SEK 7,821 million, representing a 5% increase, with 16% growth at constant exchange rates (CER). This growth was largely attributed to a substantial rise in Haematology revenue, which surged by 25% at CER, totaling SEK 5,143 million. Such strength was driven primarily by robust sales of key products, including Altuvoct and Doptelet, generating SEK 1,023 million and SEK 1,508 million, respectively.
Immunology Performance
Immunology revenues displayed modest growth, increasing by 2% at CER and amounting to SEK 2,337 million. Key drivers included strong sales of Gamifant generating SEK 763 million and Kineret at SEK 741 million, although this was slightly offset by a decline in Beyfortus royalties.
Strategic Portfolio Growth
The strategic portfolio, crucial for Sobi’s future orientation, witnessed a remarkable growth of 37% at CER, amounting to SEK 5,059 million. This segment highlights Sobi's commitment to maximizing innovative treatments for rare diseases, reflecting in its adjusted EBITA margin, which stood at a notable 41% while achieving SEK 3,075 million in EBITA, a margin improvement from the previous year.
Full Year 2025 Performance Overview
For the entire 2025 fiscal year, Sobi’s total revenue was SEK 28,238 million, marking an 8% increase overall, with a robust 15% growth at CER. The performance distinctions were evident in Haematology, with a substantial 23% growth, reinforcing Sobi’s strength in this area. While the Immunology segment grew modestly by 1%, Sobi's overall performance demonstrates resilience and strategic focus on key therapeutics to enhance patient care.
Looking Towards 2026
As Sobi looks to the future, projections indicate anticipated revenue growth at low double-digit percentages at CER for 2026, coupled with an expected adjusted EBITA margin within the mid-30% range of total revenue. This structured outlook provides a clear vision as they continue to expand their market reach.
Investor Engagement and Upcoming Conference
Investors, analysts, and interested stakeholders are encouraged to join the forthcoming conference call, set for 13:00 CET, where detailed discussions about the results will take place alongside a Q&A session. This interactive opportunity allows stakeholders to engage directly with Sobi’s management about their strategies and future direction.
About Sobi
Sobi is a leading global biopharma company dedicated to improving the lives of individuals living with rare diseases by developing innovative therapies. With approximately 1,900 employees worldwide and a total revenue reaching SEK 28 billion in 2025, Sobi's stock (STO:SOBI) is a key component listed on Nasdaq Stockholm. For more information about Sobi and its pioneering work within the healthcare sector, you can visit their official website.
Frequently Asked Questions
What financial metrics did Sobi achieve in Q4 2025?
In Q4 2025, Sobi reported total revenue of SEK 7,821 million, a 5% increase year-on-year.
How did the Haematology segment perform in 2025?
The Haematology revenue surged by 25% at CER to SEK 5,143 million, driven by strong sales performance in key products.
What outlook does Sobi provide for 2026?
Sobi anticipates growth at low double-digit percentages at constant exchange rates and a mid-30% EBITA margin.
When is the upcoming investor conference call?
The investor conference call is scheduled for 13:00 CET, where management will discuss the financial results.
What is Sobi’s mission as a biopharma company?
Sobi aims to unlock potential breakthrough innovations, transforming the lives of individuals facing rare diseases through advanced therapies.
